| Dr David Scott Johnson, MD | |
|
253 Pleasant St, Dartmouth Hitchcock - Primary Care, Concord, NH 03301-7560 | |
| (603) 226-2200 | |
| Not Available |
| Full Name | Dr David Scott Johnson |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 40 Years |
| Location | 253 Pleasant St, Concord, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053575779 | NPI | - | NPPES |
| 3074069 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 8755 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Concord Regional Vna | Concord, NH | Home health agency |
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Concord Hospital | Concord, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mary Hitchcock Memorial Hospital | 4486561164 | 964 |
News Archive
The two researchers are among the first to address the issue of drug shortages in contexts outside of the US; their study will look at the supply of medicines in Europe, with a focus on Germany, Austria and Switzerland.
A son's passion to find a cure for the cancer that claimed the life of his mother has led to a new series of clinical trials under a Translational Genomics Research Institute (TGen) initiative to find a cure for pancreatic cancer.
UCSF researchers are reporting the first success in very rapidly purifying one type of embryonic stem cell from a mix of many different types of embryonic stem cells in the culture dish. The technique, which avoids the need to genetically alter the cells to distinguish them, is a key advance, the researchers say, for obtaining the appropriate cells for repairing specific damaged tissues.
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
A new study has shown that people who have a psychiatric condition called intermittent explosive disorder (IED) are twice as likely to have been exposed to toxoplasma gondii, the parasite found in cat feces and undercooked meat.
› Verified 5 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386697803 PECOS PAC ID: 4183537509 Enrollment ID: O20031111000313 |
News Archive
The two researchers are among the first to address the issue of drug shortages in contexts outside of the US; their study will look at the supply of medicines in Europe, with a focus on Germany, Austria and Switzerland.
A son's passion to find a cure for the cancer that claimed the life of his mother has led to a new series of clinical trials under a Translational Genomics Research Institute (TGen) initiative to find a cure for pancreatic cancer.
UCSF researchers are reporting the first success in very rapidly purifying one type of embryonic stem cell from a mix of many different types of embryonic stem cells in the culture dish. The technique, which avoids the need to genetically alter the cells to distinguish them, is a key advance, the researchers say, for obtaining the appropriate cells for repairing specific damaged tissues.
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
A new study has shown that people who have a psychiatric condition called intermittent explosive disorder (IED) are twice as likely to have been exposed to toxoplasma gondii, the parasite found in cat feces and undercooked meat.
› Verified 5 days ago
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
The two researchers are among the first to address the issue of drug shortages in contexts outside of the US; their study will look at the supply of medicines in Europe, with a focus on Germany, Austria and Switzerland.
A son's passion to find a cure for the cancer that claimed the life of his mother has led to a new series of clinical trials under a Translational Genomics Research Institute (TGen) initiative to find a cure for pancreatic cancer.
UCSF researchers are reporting the first success in very rapidly purifying one type of embryonic stem cell from a mix of many different types of embryonic stem cells in the culture dish. The technique, which avoids the need to genetically alter the cells to distinguish them, is a key advance, the researchers say, for obtaining the appropriate cells for repairing specific damaged tissues.
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
A new study has shown that people who have a psychiatric condition called intermittent explosive disorder (IED) are twice as likely to have been exposed to toxoplasma gondii, the parasite found in cat feces and undercooked meat.
› Verified 5 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
The two researchers are among the first to address the issue of drug shortages in contexts outside of the US; their study will look at the supply of medicines in Europe, with a focus on Germany, Austria and Switzerland.
A son's passion to find a cure for the cancer that claimed the life of his mother has led to a new series of clinical trials under a Translational Genomics Research Institute (TGen) initiative to find a cure for pancreatic cancer.
UCSF researchers are reporting the first success in very rapidly purifying one type of embryonic stem cell from a mix of many different types of embryonic stem cells in the culture dish. The technique, which avoids the need to genetically alter the cells to distinguish them, is a key advance, the researchers say, for obtaining the appropriate cells for repairing specific damaged tissues.
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
A new study has shown that people who have a psychiatric condition called intermittent explosive disorder (IED) are twice as likely to have been exposed to toxoplasma gondii, the parasite found in cat feces and undercooked meat.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Scott Johnson, MD 253 Pleasant St, Dartmouth Hitchcock - Primary Care, Concord, NH 03301-7560 Ph: (603) 226-2200 | Dr David Scott Johnson, MD 253 Pleasant St, Dartmouth Hitchcock - Primary Care, Concord, NH 03301-7560 Ph: (603) 226-2200 |
News Archive
The two researchers are among the first to address the issue of drug shortages in contexts outside of the US; their study will look at the supply of medicines in Europe, with a focus on Germany, Austria and Switzerland.
A son's passion to find a cure for the cancer that claimed the life of his mother has led to a new series of clinical trials under a Translational Genomics Research Institute (TGen) initiative to find a cure for pancreatic cancer.
UCSF researchers are reporting the first success in very rapidly purifying one type of embryonic stem cell from a mix of many different types of embryonic stem cells in the culture dish. The technique, which avoids the need to genetically alter the cells to distinguish them, is a key advance, the researchers say, for obtaining the appropriate cells for repairing specific damaged tissues.
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
A new study has shown that people who have a psychiatric condition called intermittent explosive disorder (IED) are twice as likely to have been exposed to toxoplasma gondii, the parasite found in cat feces and undercooked meat.
› Verified 5 days ago
Patrick Cassell, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 246 Pleasant St, Suite 103, Concord, NH 03301 Phone: 603-224-6070 Fax: 603-224-6994 | |
Dr. Michael A Ferguson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 246 Pleasant Street Memorial Building, West, Ground Flo, Concord, NH 03301 Phone: 603-224-6070 Fax: 603-224-6094 | |
Dr. Clayton Theron Jones, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 246 Pleasant St, Suite 103, Concord, NH 03301 Phone: 603-224-6070 Fax: 603-224-6094 | |
Frederick M Briccetti, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant Street, New Hampshire Oncology Hematology Pa, Concord, NH 03301 Phone: 603-224-2556 Fax: 603-226-5821 | |
Dr. Patrick Magnus, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 246 Pleasant Street Memorial Building, West, Ground Flo, Concord, NH 03301 Phone: 603-224-6070 Fax: 603-224-6094 | |
Dr. Celia Ann Englander, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 281 N State St, Concord, NH 03301 Phone: 603-271-6064 |